What’s New in Ontosight® Terminal 1.1 A Complete Guide toRead More
Innoplexus Consulting Services is Proud to Announce ISO/IEC 27001:2013 Certification
Pune, India, February 13, 2020 – Innoplexus Consulting Services Private Limited, a subsidiary of Innoplexus AG, is delighted to have been awarded ISO/IEC 27001:2013 certification, a global standard for reducing the risk and improving the security of data. Innoplexus has been committed to achieving the highest levels of security compliance. This accreditation further cements Innoplexus’ efforts to maximize protection of its clients’ and key stakeholders’ valuable data and information assets.
Commitment to Continuous Improvement
Innoplexus is committed to continually improving its Information Security Management System (ISMS). The implementation team based in Pune, India, underwent an extensive company-wide audit that included a process-based approach for establishing, implementing, operating, monitoring, maintaining, and improving ISMS.
ISO is one of the most well-respected global standards. Innoplexus was audited by Perry Johnson Registrars and was presented with its certificate on 13th February 2020.
Innoplexus Consulting Services Managing director, Abhijit Keskar said, “Achieving ISO/IEC 27001:2013 certification is fantastic news and means our customers have complete assurance that their confidential information is secure with us.” He thanked the project team adding, “It proves theirs and the company’s commitment to ensuring the best ISMS for our clients.”
Innoplexus is a leading global AI-technology solution provider with over 300 employees and 100+ patent applications including 12 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus applies its proprietary tech stack at all stages of the drug development value chain, through smart Data as a Service (DaaS) and Continuous Analytics as a Service (CAaS) solutions. These solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…